Recent News

• 03.04.2025 - Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
• 03.04.2025 - Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
• 03.04.2025 - Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
• 03.04.2025 - Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
• 02.27.2025 - Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
• 02.27.2025 - Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
• 02.27.2025 - Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
• 02.27.2025 - Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
• 02.25.2025 - Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
• 02.25.2025 - Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Recent Filings

• 03.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.04.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]